All Interventions

    Dulaglutide

    Pharmaceuticals
    GLP-1 Receptor Agonists

    Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist with proven cardiovascular benefits and a user-friendly auto-injector. It offers moderate efficacy with strong adherence due to its simple delivery system.

    Evidence Summary

    8
    / 10Score
    Strong
    Good Clinical Evidence

    REWIND (Lancet, 2019; n=9,901; median 5.4 years) showed a 12% reduction in major adverse cardiovascular events (HR 0.88, 95% CI 0.79-0.99; p=0.026), notable for including a primary-prevention population (31% without established cardiovascular disease). Exploratory REWIND analyses also reported a 15% reduction in a composite kidney outcome (HR 0.85, 95% CI 0.77-0.93; p=0.0004) — driven by a 23% reduction in new macroalbuminuria (HR 0.77) — and, after adjustment for baseline scores, a 14% reduction in substantive cognitive impairment (HR 0.86, 95% CI 0.79-0.95; p=0.0018). In the head-to-head SURPASS-CVOT trial (JAMA Cardiology, 2026; n=13,165; median 46.9 months), dulaglutide 1.5 mg served as the active comparator: tirzepatide reduced a composite cardiorenal endpoint by a further 16% versus dulaglutide (HR 0.84, 95% CI 0.79-0.90; p<0.001). Dulaglutide remains a well-tolerated, cardiovascular-outcomes-proven GLP-1 option, with more potent agents now available for patients prioritizing weight loss. These are summaries of published research, not treatment claims.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    GLP-1 receptor agonist fused to a modified IgG4 Fc fragment, extending half-life to ~5 days. Enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety through central nervous system GLP-1 receptor activation.

    Who Is This For?

    Type 2 diabetes with cardiovascular risk. Patients prioritizing device simplicity. Primary cardiovascular prevention in diabetic patients.

    Protocol & Dosing

    Dose

    Start 0.75mg weekly for 4 weeks, then increase to 1.5mg weekly. Maximum dose: 4.5mg weekly.

    Frequency

    Weekly injection

    Duration

    Ongoing / Long-term

    Protocol Summary

    Weekly subcutaneous injection via pre-filled auto-injector. REWIND trial uniquely included primary CV prevention population. Moderate efficacy but highest ease-of-use rating.

    Interactions & Precautions

    Contraindications

    • Medullary thyroid carcinoma history
    • MEN2
    • Severe GI disease
    • Pancreatitis history

    Potential Risks

    • •Thyroid tumor risk
    • •Pancreatitis
    • •Gallbladder events

    Potential Side Effects

    Nausea
    Diarrhea
    Abdominal pain
    Decreased appetite
    Fatigue

    Practitioner Notes

    Clinical annotations from Dr. Goel

    Good option for patients who value simple injection technique and a long safety record. Less weight loss than semaglutide or tirzepatide — manage expectations. Strong choice for primary cardiovascular prevention in diabetes based on REWIND, with exploratory signals for kidney and cognitive protection. The 2026 SURPASS-CVOT head-to-head used dulaglutide 1.5 mg as the active comparator and found tirzepatide superior on the composite cardiorenal endpoint, so consider upgrading when greater metabolic potency is the goal. Educational information, not medical advice.
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Latest Evidence

    2024-2026: where dulaglutide stands among the GLP-1s

    Dulaglutide (Trulicity) is one of the most thoroughly studied once-weekly GLP-1 receptor agonists. Its landmark REWIND trial (Lancet, 2019; 9,901 participants, median 5.4 years) remains distinctive for enrolling a large primary-prevention group - 31% had no established cardiovascular disease - and still showed a 12% reduction in major adverse cardiovascular events (HR 0.88, 95% CI 0.79-0.99; p=0.026). Exploratory REWIND analyses pointed to protection beyond the heart: a 15% lower composite kidney outcome (HR 0.85, 95% CI 0.77-0.93), led by a 23% drop in new macroalbuminuria, and - after adjustment for baseline scores - a 14% reduction in substantive cognitive impairment (HR 0.86, 95% CI 0.79-0.95; p=0.0018).

    The newest head-to-head data reframe where dulaglutide sits in 2026. In SURPASS-CVOT (JAMA Cardiology, 2026; 13,165 patients with type 2 diabetes and established cardiovascular disease, median 46.9 months), dulaglutide 1.5 mg was the active comparator against tirzepatide. Tirzepatide reduced a six-component composite cardiorenal endpoint by a further 16% versus dulaglutide (HR 0.84, 95% CI 0.79-0.90; p<0.001), including lower all-cause mortality (HR 0.84) and fewer kidney events (HR 0.79). The practical read: dulaglutide delivers robust, well-tolerated, outcomes-proven benefit, while more potent incretins now offer incremental cardiorenal and weight advantages for suitable patients.

    Dulaglutide is FDA- and Health Canada-approved for type 2 diabetes; it is not approved for cognitive or kidney indications, and the cognitive and renal findings above are exploratory. These are summaries of published research, not treatment claims. Educational information, not medical advice - discuss any GLP-1 therapy with a qualified clinician.

    REWIND trial · 9,901 participants · median 5.4 years · type 2 diabetes

    Dulaglutide vs placebo - relative risk reduction across organ systems

    Longer bar = greater risk reduction vs placebo →

    Source: REWIND, Lancet (2019) and its exploratory kidney (Lancet, 2019) and cognitive (Lancet Neurology, 2020) analyses; NCT01394952, 9,901 participants, median 5.4 years. The cardiovascular endpoint was the trial's primary outcome; the cognitive and kidney results are exploratory (shown in a lighter tone) and need confirmation. Dulaglutide is approved for type 2 diabetes, not for cognitive or kidney indications. Educational summary of published research, not a treatment claim.

    Key references: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) - The Lancet (2019) · Effect of dulaglutide on cognitive impairment in type 2 diabetes (REWIND exploratory analysis) - The Lancet Neurology (2020) · Dulaglutide and renal outcomes in type 2 diabetes (REWIND exploratory analysis) - The Lancet (2019) · Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide (SURPASS-CVOT post hoc analysis) - JAMA Cardiology (2026)

    Cost & Access

    Cost Range

    $$$

    Accessibility

    Prescription Required

    Availability varies by location

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation